Silence Therapeutics plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Steven Romano, was filed 03 Dec 2020.
Silence Therapeutics plc: what insiders have been doing
Silence Therapeutics plc is a listed company. Filings by its managers are published through RNS (LSE). Silence Therapeutics plc has had no insider filing for more than a year; the last one goes back to 3 December 2020.
Over the whole record (from 2016), the tally stands at 12 purchases and no sales.
Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.
Since the insiders bought
- +51.0%Entry 4.95 · Close at T+365 7.47
- +48.5%Entry 4.95 · Close at T+365 7.35
- +48.5%Entry 4.95 · Close at T+365 7.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
- 4,500 sharesOutside a trading venueISIN GB00B9GTXM62FCA-NSM:3802673Canonical exit: 28 Feb 2021 (T+90)
- 1,258 shares@ £3.968630.9% of flowLondon Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:3751051Canonical exit: 12 Jan 2021 (T+90)
- 9,750 shares@ £4.1045.4% of flowLondon Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:3745650-0Canonical exit: 6 Jan 2021 (T+90)
- 1,250 shares@ £4.0039.4% of flowLondon Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:3745650-1Canonical exit: 7 Jan 2021 (T+90)
- 3,000 shares@ £4.0875100.0% of flowLondon Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:3745650-2Canonical exit: 6 Jan 2021 (T+90)
- 4,945 shares@ £4.04100.0% of flowLondon Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:3745650-3Canonical exit: 7 Jan 2021 (T+90)
- 4,000 shares@ £1.86100.0% of flowExercise - Outside a trading venue Purchase - London Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:LSE20191004172101_14255305_20200326185155804_31146Canonical exit: 2 Jan 2020 (T+90)
- 3,171 shares@ £1.8998.7% of flowLondon Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:LSE20191003154008_14253413_20200326185156039_32916Canonical exit: 31 Dec 2019 (T+90)
- 10,000 shares@ £1.93100.0% of flowLondon Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:LSE20191002170914_14251761_20200326185156245_34505Canonical exit: 31 Dec 2019 (T+90)
- 1,626 shares@ £0.051.3% of flowOutside a trading venueISIN GB00B9GTXM62FCA-NSM:LSE20191001180637_14249968_20200326185156367_36210
- 25,000 shares@ £1.88100.0% of flowLondon Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:LSE20190930170906_14247696_20200326185201454_155Canonical exit: 29 Dec 2019 (T+90)
- 3,848 shares@ £1.297545.0% of flowLondon Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:LSE20170803070008_13317715_20200330131542791_2198Canonical exit: 31 Oct 2017 (T+90)
- 7,000 shares@ £1.4688100.0% of flowLondon Stock Exchange, AIMISIN GB00B9GTXM62FCA-NSM:LSE20170731114339_13313173_20200330131519867_21543Canonical exit: 29 Oct 2017 (T+90)
- 200,000 shares@ £1.1062100.0% of flowLondon Stock Exchange, AIMFCA-NSM:LSE20160718070009_012895268_20200330143558367_12760
14 of 14 declarations
About Silence Therapeutics plc
Silence Therapeutics plc is a biopharmaceutical company focused on developing RNA-based therapies for serious diseases. It emphasizes innovation in the field of genomic medicine.
